Christopher S. F. Low

Array ( [id] => 5464525 [patent_doc_number] => 20090324725 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-12-31 [patent_title] => 'PEG-MODIFIED HYDROXYAPATITE, PHARMACEUTICAL USING THE SAME AS BASE MATERIAL AND PRODUCTION PROCESS THEREOF' [patent_app_type] => utility [patent_app_number] => 12/358486 [patent_app_country] => US [patent_app_date] => 2009-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 6514 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0324/20090324725.pdf [firstpage_image] =>[orig_patent_app_number] => 12358486 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5285449 [patent_doc_number] => 20090099124 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-04-16 [patent_title] => 'SHORT INTERFERING RNA AS AN ANTIVIRAL AGENT FOR HEPATITIS C' [patent_app_type] => utility [patent_app_number] => 12/326508 [patent_app_country] => US [patent_app_date] => 2008-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 6213 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0099/20090099124.pdf [firstpage_image] =>[orig_patent_app_number] => 12326508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5310816 [patent_doc_number] => 20090018097 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-01-15 [patent_title] => 'MODIFICATION OF DOUBLE-STRANDED RIBONUCLEIC ACID MOLECULES' [patent_app_type] => utility [patent_app_number] => 12/065604 [patent_app_country] => US [patent_app_date] => 2006-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 29562 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0018/20090018097.pdf [firstpage_image] =>[orig_patent_app_number] => 12065604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5754625 [patent_doc_number] => 20060223774 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-10-05 [patent_title] => 'Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof' [patent_app_type] => utility [patent_app_number] => 11/375690 [patent_app_country] => US [patent_app_date] => 2006-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 42705 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0223/20060223774.pdf [firstpage_image] =>[orig_patent_app_number] => 11375690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5620025 [patent_doc_number] => 20060189559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-08-24 [patent_title] => 'Method and system for treating hepatitis C' [patent_app_type] => utility [patent_app_number] => 11/305707 [patent_app_country] => US [patent_app_date] => 2005-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 2707 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0189/20060189559.pdf [firstpage_image] =>[orig_patent_app_number] => 11305707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5310812 [patent_doc_number] => 20090018093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-01-15 [patent_title] => 'Nucleic Acid Ligands Specific to Immunoglobuline E and Their Use as Atopic Disease Therapeutics' [patent_app_type] => utility [patent_app_number] => 11/885902 [patent_app_country] => US [patent_app_date] => 2005-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 44073 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0018/20090018093.pdf [firstpage_image] =>[orig_patent_app_number] => 11885902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5656494 [patent_doc_number] => 20060142230 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-06-29 [patent_title] => 'Double-stranded ribonucleic acid molecules having ribothymidine' [patent_app_type] => utility [patent_app_number] => 11/219625 [patent_app_country] => US [patent_app_date] => 2005-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 11766 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0142/20060142230.pdf [firstpage_image] =>[orig_patent_app_number] => 11219625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7250323 [patent_doc_number] => 20050272682 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-12-08 [patent_title] => 'SiRNA targeting PI3K signal transduction pathway and siRNA-based therapy' [patent_app_type] => utility [patent_app_number] => 11/085962 [patent_app_country] => US [patent_app_date] => 2005-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 13081 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0272/20050272682.pdf [firstpage_image] =>[orig_patent_app_number] => 11085962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4989341 [patent_doc_number] => 20070155682 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-07-05 [patent_title] => 'Translational control by small, non-translatable rnas' [patent_app_type] => utility [patent_app_number] => 10/534789 [patent_app_country] => US [patent_app_date] => 2003-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 24179 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0155/20070155682.pdf [firstpage_image] =>[orig_patent_app_number] => 10534789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6725019 [patent_doc_number] => 20030207331 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-11-06 [patent_title] => 'Encoding methods using up-converting phosphors for high-throughput screening of catalysts' [patent_app_type] => new [patent_app_number] => 10/410234 [patent_app_country] => US [patent_app_date] => 2003-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 15202 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0207/20030207331.pdf [firstpage_image] =>[orig_patent_app_number] => 10410234 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4328544 [patent_doc_number] => 06319896 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-11-20 [patent_title] => 'Method of solubilizing, purifying, and refolding protein' [patent_app_type] => 1 [patent_app_number] => 9/443098 [patent_app_country] => US [patent_app_date] => 1999-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 37 [patent_no_of_words] => 15853 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/319/06319896.pdf [firstpage_image] =>[orig_patent_app_number] => 443098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1475592 [patent_doc_number] => 06388054 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-05-14 [patent_title] => 'Anti-cancer compounds' [patent_app_type] => B1 [patent_app_number] => 09/378019 [patent_app_country] => US [patent_app_date] => 1999-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 10996 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/388/06388054.pdf [firstpage_image] =>[orig_patent_app_number] => 09378019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4274846 [patent_doc_number] => 06323326 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-11-27 [patent_title] => 'Method of solubilizing, purifying, and refolding protein' [patent_app_type] => 1 [patent_app_number] => 8/973211 [patent_app_country] => US [patent_app_date] => 1999-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 39 [patent_no_of_words] => 15757 [patent_no_of_claims] => 69 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/323/06323326.pdf [firstpage_image] =>[orig_patent_app_number] => 973211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3998913 [patent_doc_number] => 05858721 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-01-12 [patent_title] => 'Three-dimensional cell and tissue culture system' [patent_app_type] => 1 [patent_app_number] => 8/978520 [patent_app_country] => US [patent_app_date] => 1997-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 27316 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/858/05858721.pdf [firstpage_image] =>[orig_patent_app_number] => 978520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4044067 [patent_doc_number] => 05912159 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-06-15 [patent_title] => 'Arginase II' [patent_app_type] => 1 [patent_app_number] => 8/914981 [patent_app_country] => US [patent_app_date] => 1997-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 24314 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/912/05912159.pdf [firstpage_image] =>[orig_patent_app_number] => 914981 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4045078 [patent_doc_number] => 05908785 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-06-01 [patent_title] => 'Compositions and methods for use in controlling insect populations' [patent_app_type] => 1 [patent_app_number] => 8/871011 [patent_app_country] => US [patent_app_date] => 1997-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 6310 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/908/05908785.pdf [firstpage_image] =>[orig_patent_app_number] => 871011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3964326 [patent_doc_number] => 05885836 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-03-23 [patent_title] => 'FLP-mediated gene modification in mammalian cells, and compositions and cells useful therefor' [patent_app_type] => 1 [patent_app_number] => 8/825784 [patent_app_country] => US [patent_app_date] => 1997-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 7 [patent_no_of_words] => 7465 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/885/05885836.pdf [firstpage_image] =>[orig_patent_app_number] => 825784 [rel_patent_id] =>[rel_patent_doc_number] =>)